|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500109275 |
|
最近更新日期: Date of Last Refreshed on: |
2025-09-16 10:38:15 |
|
注册时间: Date of Registration: |
2025-09-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
术中伤害指数(qNOX)监测对行结直肠手术的老年患者围术期阿片类药物的用量以及术后恢复的影响 |
|
Public title: |
Effect of quantium noxious index (qNOX) monitoring on perioperative opioid consumption and postoperative recovery in elderly patients undergoing colorectal surgery |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
术中伤害指数(qNOX)监测对行结直肠手术的老年患者围术期阿片类药物的用量以及术后恢复的影响 |
|
Scientific title: |
Effect of quantium noxious index (qNOX) monitoring on perioperative opioid consumption and postoperative recovery in elderly patients undergoing colorectal surgery |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄松高 |
研究负责人: |
李云胜 |
|
Applicant: |
Songgao Huang |
Study leader: |
Yunsheng Li |
|
申请注册联系人电话: Applicant telephone: |
+86 138 7049 5610 |
研究负责人电话:
Study leader's |
+86 137 6086 3235 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liysheng@mail.sysu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
liysheng@mail.sysu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省广州市越秀区中山二路58号 |
研究负责人通讯地址: |
中国广东省广州市越秀区中山二路58号 |
|
Applicant address: |
58 Second Zhongshan Road, Guangzhou, Guangdong, China |
Study leader's address: |
58 Second Zhongshan Road, Guangzhou, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
510080 |
研究负责人邮政编码: Study leader's postcode: |
510080 |
|
申请人所在单位: |
中山大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Sun Yat-sen University |
||
|
研究负责人所在单位: |
中山大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Sun Yat-sen University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审临[2025]349 号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第一医院临床科研和实验动物伦理委员会 |
||
|
Name of the ethic committee: |
IEC for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-10 00:00:00 | ||
|
伦理委员会联系人: |
颜楚荣 |
||
|
Contact Name of the ethic committee: |
Churong Yan |
||
|
伦理委员会联系地址: |
广州市中山二路58号,中山大学附属第一医院临床科研和实验动物伦理委员会 |
||
|
Contact Address of the ethic committee: |
Clinical Research and Laboratory Animal Ethics Committee, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan 2nd Road, Guangzhou, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8733 4871 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中山大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Sun Yat-sen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市中山二路58号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
58 Second Zhongshan Road, Guangzhou, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
急性术后疼痛 |
||||||||||||||||||||||
|
Target disease: |
Acute postoperative pain |
||||||||||||||||||||||
|
研究疾病代码: |
MG31.2 |
||||||||||||||||||||||
|
Target disease code: |
MG31.2 |
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
主要目的:本实验旨在探讨在结直肠手术过程中,伤害指数qNOX指导对全身麻醉围术期术中阿片类药物用量的影响。 次要目的:在伤害指数qNOX监测下瑞芬太尼的使用方案能否减少术中不良事件发生率、降低患者术后疼痛水平以及改善患者预后。 |
||||||||||||||||||||||
|
Objectives of Study: |
Main Objective: This experiment aims to explore the effect of the injury index qNOX guidance on opioid dosage during colorectal surgery. Secondary Objective: Can the use of remifentanil be used under the monitoring of the injury index qNOX to reduce the incidence of intraoperative adverse events, reduce the postoperative pain level of patients, and improve the prognosis of patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1: 年龄:65-90岁老年患者,男女不限; 2: 美国麻醉医师学会ASA分级:Ⅰ-Ⅲ级; 3: 全身麻醉下行腹腔镜结直肠手术; 4: 预计手术时间60min以上,术后转PACU ; 5: 遵守本试验程序,并自愿签署知情同意书; |
||||||||||||||||||||||
|
Inclusion criteria |
1: Age: Elderly patients aged 65-90, male and female, no limit; 2: ASA classification of the American Academy of Anesthesiologists: Grades I-III; 3: Laparoscopic colorectal surgery under general anesthesia; 4: the estimated operation time is more than 60 minutes, and the postoperative transfer to PACU; 5: comply with this test procedure and voluntarily sign an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1: 无法获得知情同意的患者; 2: 急诊手术; 3: 非全身麻醉手术; 4: 已知对麻醉药物过敏或不耐受的患者; 5: 术前存在急性或慢性疼痛或有长期阿片类或非阿片类止痛药使用史; 6: 外周或中枢神经系统紊乱; 7: 明确诊断的精神疾病史或其他影响严重认知障碍判断的神经或精神疾病史,精神药物使用史; 8: 基础平均动脉压(MAP)小于60mm Hg或大于120mm Hg,基础心率(HR)小于45次/分钟或大于120mm Hg; 9: 严重基础疾病史,如未经治疗或持续性外周或中枢心血管疾病、严重肝脏或肾脏疾病、严重肺部疾病。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1: Patients who cannot obtain informed consent; 2: emergency surgery; 3: non-general anesthesia surgery; 4: patients who are known to be allergic to or intolerant to anesthetic drugs; 5: acute or chronic pain before surgery or a long-term use of opioid or non-opioid pain medications; 6: peripheral or central nervous system disorders; 7: clear history of diagnosed mental illness or other history of neurological or mental illness that affects the judgment of severe cognitive impairment, and history of psychotropic drugs; 8: basal mean arterial pressure (MAP) is less than 60 mmHg or greater than 120 mmHg, basal heart rate (HR) is less than 45 beats/minute or greater than 120 mmHg; 9: history of severe underlying diseases, such as untreated or persistent peripheral or central cardiovascular disease, severe liver or renal disease, and severe pulmonary disease. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-20 00:00:00至 To 2026-02-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-09-20 00:00:00 至 To 2026-02-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
简单随机,由独立人员采用SPSS软件进行随机分组,分组信息由信封保存,仅在患者入手术室后麻醉医生方可知, |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Simple and random, independent personnel use SPSS software for random grouping. The grouping information is saved in envelopes. Only after the patient enters the operating room can the anesthesiologist know. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲(对受试者隐藏分组),对评估者隐藏分组 |
|
Blinding: |
Single-blind (hidden grouping for subjects), hidden grouping for assessors |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表(Case Record Form, CRF) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |